{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T00:55:40Z","timestamp":1780707340447,"version":"3.54.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"vor","delay-in-days":54,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100018552","name":"Science and Technology Plan Project of Taizhou","doi-asserted-by":"publisher","award":["No. 25ywb102"],"award-info":[{"award-number":["No. 25ywb102"]}],"id":[{"id":"10.13039\/501100018552","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Innovation and Entrepreneurship Training Program for College Students","award":["No. 202510343083"],"award-info":[{"award-number":["No. 202510343083"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 82302081"],"award-info":[{"award-number":["No. 82302081"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Zhejiang Provincial Natural Science Foundation of China","award":["No. LQ24H090003"],"award-info":[{"award-number":["No. LQ24H090003"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Parkinsons Dis."],"DOI":"10.1038\/s41531-026-01308-9","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T21:03:14Z","timestamp":1773954194000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Age at onset of Parkinson\u2019s disease modulates the sphingolipid-dopaminergic interplay in autonomic progression"],"prefix":"10.1038","volume":"12","author":[{"given":"Zhinan","family":"Ye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shishu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zijia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junchao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xicheng","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyi","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuoyu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zihan","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suwen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiyun","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dehao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,19]]},"reference":[{"key":"1308_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2024.1498756","volume":"16","author":"Y Luo","year":"2024","unstructured":"Luo, Y. et al. Global, regional, national epidemiology and trends of Parkinson\u2019s disease from 1990 to 2021: findings from the Global Burden of Disease Study 2021. Front Aging Neurosci. 16, 1498756 (2024).","journal-title":"Front Aging Neurosci."},{"key":"1308_CR2","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/s41746-024-01217-2","volume":"7","author":"YM Sun","year":"2024","unstructured":"Sun, Y. M., Wang, Z. Y., Liang, Y. Y., Hao, C. W. & Shi, C. H. Digital biomarkers for precision diagnosis and monitoring in Parkinson\u2019s disease. NPJ Digit Med 7, 218 (2024).","journal-title":"NPJ Digit Med"},{"key":"1308_CR3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41531-023-00623-9","volume":"10","author":"Y Huang","year":"2024","unstructured":"Huang, Y. et al. Risk factors associated with age at onset of Parkinson\u2019s disease in the UK Biobank. NPJ Parkinsons Dis. 10, 3 (2024).","journal-title":"NPJ Parkinsons Dis."},{"key":"1308_CR4","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1002\/mdc3.13523","volume":"9","author":"R Mehanna","year":"2022","unstructured":"Mehanna, R. et al. Age Cutoff for Early-Onset Parkinson\u2019s Disease: Recommendations from the International Parkinson and Movement Disorder Society Task Force on Early Onset Parkinson\u2019s Disease. Mov. Disord. Clin. Pr. 9, 869\u2013878 (2022).","journal-title":"Mov. Disord. Clin. Pr."},{"key":"1308_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-04356-8","volume":"12","author":"LL Raket","year":"2022","unstructured":"Raket, L. L. et al. Impact of age at onset on symptom profiles, treatment characteristics and health-related quality of life in Parkinson\u2019s disease. Sci. Rep. 12, 526 (2022).","journal-title":"Sci. Rep."},{"key":"1308_CR6","doi-asserted-by":"publisher","first-page":"3472","DOI":"10.1093\/brain\/awac176","volume":"145","author":"J Galper","year":"2022","unstructured":"Galper, J. et al. Lipid pathway dysfunction is prevalent in patients with Parkinson\u2019s disease. Brain 145, 3472\u20133487 (2022).","journal-title":"Brain"},{"key":"1308_CR7","doi-asserted-by":"publisher","first-page":"328","DOI":"10.3389\/fnins.2019.00328","volume":"13","author":"I Alecu","year":"2019","unstructured":"Alecu, I. & Bennett, S. A. L. Dysregulated Lipid Metabolism and Its Role in \u03b1-Synucleinopathy in Parkinson\u2019s Disease. Front Neurosci. 13, 328 (2019).","journal-title":"Front Neurosci."},{"key":"1308_CR8","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.cell.2011.06.001","volume":"146","author":"JR Mazzulli","year":"2011","unstructured":"Mazzulli, J. R. et al. Gaucher disease glucocerebrosidase and \u03b1-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 146, 37\u201352 (2011).","journal-title":"Cell"},{"key":"1308_CR9","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.neuron.2017.12.012","volume":"97","author":"F Zunke","year":"2018","unstructured":"Zunke, F. et al. Reversible Conformational Conversion of \u03b1-Synuclein into Toxic Assemblies by Glucosylceramide. Neuron 97, 92\u2013107.e110 (2018).","journal-title":"Neuron"},{"key":"1308_CR10","doi-asserted-by":"publisher","first-page":"7485","DOI":"10.1073\/pnas.1804266115","volume":"115","author":"AK Rudd","year":"2018","unstructured":"Rudd, A. K. & Devaraj, N. K. Traceless synthesis of ceramides in living cells reveals saturation-dependent apoptotic effects. Proc. Natl. Acad. Sci. USA 115, 7485\u20137490 (2018).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1308_CR11","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1111\/tra.12239","volume":"16","author":"T Yamaji","year":"2015","unstructured":"Yamaji, T. & Hanada, K. Sphingolipid metabolism and interorganellar transport: localization of sphingolipid enzymes and lipid transfer proteins. Traffic 16, 101\u2013122 (2015).","journal-title":"Traffic"},{"key":"1308_CR12","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.bbalip.2015.12.021","volume":"1861","author":"DK Olson","year":"2016","unstructured":"Olson, D. K., Fr\u00f6hlich, F., Farese, R. V. Jr. & Walther, T. C. Taming the sphinx: Mechanisms of cellular sphingolipid homeostasis. Biochim Biophys. Acta 1861, 784\u2013792 (2016).","journal-title":"Biochim Biophys. Acta"},{"key":"1308_CR13","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.cmet.2018.05.019","volume":"28","author":"G Lin","year":"2018","unstructured":"Lin, G. et al. Phospholipase PLA2G6, a Parkinsonism-Associated Gene, Affects Vps26 and Vps35, Retromer Function, and Ceramide Levels, Similar to \u03b1-Synuclein Gain. Cell Metab. 28, 605\u2013618.e606 (2018).","journal-title":"Cell Metab."},{"key":"1308_CR14","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/s41531-021-00241-3","volume":"7","author":"YE Huh","year":"2021","unstructured":"Huh, Y. E. et al. Glucosylceramide in cerebrospinal fluid of patients with GBA-associated and idiopathic Parkinson\u2019s disease enrolled in PPMI. NPJ Parkinsons Dis. 7, 102 (2021).","journal-title":"NPJ Parkinsons Dis."},{"key":"1308_CR15","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1002\/ana.27219","volume":"97","author":"EN Somerville","year":"2025","unstructured":"Somerville, E. N. et al. Plasma Glucosylceramide Levels Are Regulated by ATP10D and Are Not Involved in Parkinson\u2019s Disease Pathogenesis. Ann. Neurol. 97, 873\u2013878 (2025).","journal-title":"Ann. Neurol."},{"key":"1308_CR16","doi-asserted-by":"publisher","first-page":"43933","DOI":"10.1074\/jbc.M111.241232","volume":"286","author":"J Swant","year":"2011","unstructured":"Swant, J. et al. \u03b1-Synuclein stimulates a dopamine transporter-dependent chloride current and modulates the activity of the transporter. J. Biol. Chem. 286, 43933\u201343943 (2011).","journal-title":"J. Biol. Chem."},{"key":"1308_CR17","first-page":"916","volume":"15","author":"FJ Lee","year":"2001","unstructured":"Lee, F. J., Liu, F., Pristupa, Z. B. & Niznik, H. B. Direct binding and functional coupling of alpha-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis. Faseb J. 15, 916\u2013926 (2001).","journal-title":"Faseb J."},{"key":"1308_CR18","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.tips.2013.07.005","volume":"34","author":"RA Vaughan","year":"2013","unstructured":"Vaughan, R. A. & Foster, J. D. Mechanisms of dopamine transporter regulation in normal and disease states. Trends Pharm. Sci. 34, 489\u2013496 (2013).","journal-title":"Trends Pharm. Sci."},{"key":"1308_CR19","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1002\/mdc3.13726","volume":"10","author":"I Trinh","year":"2023","unstructured":"Trinh, I., Muralidhar, A., Yang, J. & Phielipp, N. Quantified Striatal Dopaminergic Denervation as Predictor for Motor Outcomes in Parkinson\u2019s Disease. Mov. Disord. Clin. Pr. 10, 896\u2013902 (2023).","journal-title":"Mov. Disord. Clin. Pr."},{"key":"1308_CR20","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1002\/mds.27361","volume":"33","author":"T Simuni","year":"2018","unstructured":"Simuni, T. et al. Longitudinal Change of Clinical and Biological Measures in Early Parkinson\u2019s Disease: Parkinson\u2019s Progression Markers Initiative Cohort. Mov. Disord. 33, 771\u2013782 (2018).","journal-title":"Mov. Disord."},{"key":"1308_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2024.107071","volume":"126","author":"R Yang","year":"2024","unstructured":"Yang, R. et al. Plasma sphingolipids, dopaminergic degeneration and clinical progression in idiopathic Parkinson\u2019s disease. Parkinsonism Relat. Disord. 126, 107071 (2024).","journal-title":"Parkinsonism Relat. Disord."},{"key":"1308_CR22","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.2119\/molmed.2011.00119","volume":"17","author":"N Fabelo","year":"2011","unstructured":"Fabelo, N. et al. Severe alterations in lipid composition of frontal cortex lipid rafts from Parkinson\u2019s disease and incidental Parkinson\u2019s disease. Mol. Med 17, 1107\u20131118 (2011).","journal-title":"Mol. Med"},{"key":"1308_CR23","doi-asserted-by":"publisher","first-page":"11128","DOI":"10.18632\/aging.206030","volume":"16","author":"T Russo","year":"2024","unstructured":"Russo, T. & Riessland, M. Lipid accumulation drives cellular senescence in dopaminergic neurons. Aging (Albany NY) 16, 11128\u201311133 (2024).","journal-title":"Aging (Albany NY)"},{"key":"1308_CR24","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.conb.2021.11.004","volume":"72","author":"I Milenkovic","year":"2022","unstructured":"Milenkovic, I., Blumenreich, S. & Futerman, A. H. GBA mutations, glucosylceramide and Parkinson\u2019s disease. Curr. Opin. Neurobiol. 72, 148\u2013154 (2022).","journal-title":"Curr. Opin. Neurobiol."},{"key":"1308_CR25","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1038\/s41386-018-0133-6","volume":"43","author":"JJ Liu","year":"2018","unstructured":"Liu, J. J. et al. Regulation of monoamine transporters and receptors by lipid microdomains: implications for depression. Neuropsychopharmacology 43, 2165\u20132179 (2018).","journal-title":"Neuropsychopharmacology"},{"key":"1308_CR26","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.125.044903","volume":"15","author":"T Chen","year":"2026","unstructured":"Chen, T. et al. Exploring Ceramide C16:0 as a Novel Biomarker and Therapeutic Target for Atherosclerosis. J. Am. Heart Assoc. 15, e044903 (2026).","journal-title":"J. Am. Heart Assoc."},{"key":"1308_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1348410","volume":"15","author":"Y Pan","year":"2024","unstructured":"Pan, Y. et al. A review of the mechanisms of abnormal ceramide metabolism in type 2 diabetes mellitus, Alzheimer\u2019s disease, and their co-morbidities. Front Pharm. 15, 1348410 (2024).","journal-title":"Front Pharm."},{"key":"1308_CR28","doi-asserted-by":"publisher","DOI":"10.1111\/cns.70082","volume":"30","author":"X Liu","year":"2024","unstructured":"Liu, X. et al. Exploratory Analysis of the Association Between Plasma Ceramide Alterations and Cognitive Dysfunction in Parkinson\u2019s Disease. CNS Neurosci. Ther. 30, e70082 (2024).","journal-title":"CNS Neurosci. Ther."},{"key":"1308_CR29","doi-asserted-by":"publisher","first-page":"437","DOI":"10.3389\/fneur.2020.00437","volume":"11","author":"AV Alessenko","year":"2020","unstructured":"Alessenko, A. V. & Albi, E. Exploring Sphingolipid Implications in Neurodegeneration. Front Neurol. 11, 437 (2020).","journal-title":"Front Neurol."},{"key":"1308_CR30","doi-asserted-by":"publisher","unstructured":"Mesa-Herrera, F., Taoro-Gonz\u00e1lez, L., Vald\u00e9s-Baizabal, C., Diaz, M. & Mar\u00edn, R. Lipid and Lipid Raft Alteration in Aging and Neurodegenerative Diseases: A Window for the Development of New Biomarkers. Int. J. Mol. Sci. 20, https:\/\/doi.org\/10.3390\/ijms20153810 (2019).","DOI":"10.3390\/ijms20153810"},{"key":"1308_CR31","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.autneu.2018.09.005","volume":"216","author":"R Kim","year":"2019","unstructured":"Kim, R. & Jun, J. S. Association of autonomic symptoms with presynaptic striatal dopamine depletion in drug-naive Parkinson\u2019s disease: An analysis of the PPMI data. Auton. Neurosci. 216, 59\u201362 (2019).","journal-title":"Auton. Neurosci."},{"key":"1308_CR32","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1002\/mds.28986","volume":"37","author":"K Murtom\u00e4ki","year":"2022","unstructured":"Murtom\u00e4ki, K. et al. Gastrointestinal Symptoms and Dopamine Transporter Asymmetry in Early Parkinson\u2019s Disease. Mov. Disord. 37, 1284\u20131289 (2022).","journal-title":"Mov. Disord."},{"key":"1308_CR33","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1016\/j.neuroimage.2010.09.012","volume":"54","author":"E Peltz","year":"2011","unstructured":"Peltz, E. et al. Functional connectivity of the human insular cortex during noxious and innocuous thermal stimulation. Neuroimage 54, 1324\u20131335 (2011).","journal-title":"Neuroimage"},{"key":"1308_CR34","doi-asserted-by":"publisher","unstructured":"Conti, M. et al. Insular and limbic abnormal functional connectivity in early-stage Parkinson\u2019s disease patients with autonomic dysfunction. Cereb. Cortex 34, https:\/\/doi.org\/10.1093\/cercor\/bhae270 (2024).","DOI":"10.1093\/cercor\/bhae270"},{"key":"1308_CR35","unstructured":"The Parkinson Progression Marker Initiative (PPMI). Prog. Neurobiol. 95, 629\u2013635, (2011)."},{"key":"1308_CR36","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1002\/mds.26374","volume":"31","author":"MA Nalls","year":"2016","unstructured":"Nalls, M. A. et al. Baseline genetic associations in the Parkinson\u2019s Progression Markers Initiative (PPMI). Mov. Disord. 31, 79\u201385 (2016).","journal-title":"Mov. Disord."},{"key":"1308_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1413187","volume":"15","author":"LX Cao","year":"2024","unstructured":"Cao, L. X. et al. Assessment tools for cognitive performance in Parkinson\u2019s disease and its genetic contributors. Front Neurol. 15, 1413187 (2024).","journal-title":"Front Neurol."},{"key":"1308_CR38","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1002\/mds.20153","volume":"19","author":"M Visser","year":"2004","unstructured":"Visser, M., Marinus, J., Stiggelbout, A. M. & Van Hilten, J. J. Assessment of autonomic dysfunction in Parkinson\u2019s disease: the SCOPA-AUT. Mov. Disord. 19, 1306\u20131312 (2004).","journal-title":"Mov. Disord."},{"key":"1308_CR39","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41531-025-00874-8","volume":"11","author":"AE Martinez-Nunez","year":"2025","unstructured":"Martinez-Nunez, A. E. et al. Clinically probable RBD is an early predictor of malignant non-motor Parkinson\u2019s disease phenotypes. NPJ Parkinsons Dis. 11, 25 (2025).","journal-title":"NPJ Parkinsons Dis."},{"key":"1308_CR40","first-page":"1277","volume":"70","author":"JH Kang","year":"2013","unstructured":"Kang, J. H. et al. Association of cerebrospinal fluid \u03b2-amyloid 1-42, T-tau, P-tau181, and \u03b1-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. JAMA Neurol. 70, 1277\u20131287 (2013).","journal-title":"JAMA Neurol."}],"container-title":["npj Parkinson's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41531-026-01308-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-026-01308-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-026-01308-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T20:01:13Z","timestamp":1778616073000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41531-026-01308-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,19]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1308"],"URL":"https:\/\/doi.org\/10.1038\/s41531-026-01308-9","relation":{},"ISSN":["2373-8057"],"issn-type":[{"value":"2373-8057","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,19]]},"assertion":[{"value":"16 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"116"}}